BD-111

N/A

Report date: 2025/07/28 17:40:10

Base Information

Drug NameBD-111
Drug Alias NameBDmRNA-C01BD-111
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionViral genome degradersHSV replication inhibitors
TargetsNot applicable
Therapy Area/IndicationsKeratitisHerpes SimplexKeratitis, Herpetic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai BDgene Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai BDgene Co Ltd
Inactive CompaniesN/A
Active IndicationsKeratitisHerpes SimplexKeratitis, Herpetic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A